DUBLIN--(BUSINESS WIRE)--The "Companion Diagnostic Markets - the Future of Diagnostics, by Funding Source and Application with Customized Forecasting/Analysis, COVID-19 Updates, and Executive and Consultant Guides 2021-2025" report has been added to ResearchAndMarkets.com's offering.
Companion Diagnostics are poised to revolutionize the diagnostics industry. The market is finally moving out of the lab and into the clinic. Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future. But COVID-19 is impacting healthcare treatment everywhere and lowering demand for specialized cancer testing. Find out the latest outlook for this important market.
Learn all about how diagnostic players are jockeying for position with their pharmaceutical counterparts and creating new and significant business opportunities. And some players are already taking the lead. It is a dynamic market situation with enormous opportunity. Diagnostic companies are trying to back the right horse. The science is racing forward. And the cost of molecular diagnostics continues to fall.
This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Forecast demand for new testing regimes or technologies. Make research investment decisions. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth.
The report includes detailed breakouts for 18 Countries and 4 Regions.
Companion Diagnostic Market - Strategic Situation Analysis
- Guide for Executives, Marketing, Sales and Business Development Staff
- Guide for Management Consultants and Investment Advisors
Companies Mentioned
- Abbott Diagnostics
- AccuraGen Inc
- Adaptive Biotechnologies
- Aethlon Medical
- Agena Bioscience, Inc
- Agilent
- Anchor Dx
- ANGLE plc
- ApoCell, Inc.
- ArcherDx, Inc
- ARUP Laboratories
- Asuragen
- AVIVA Biosciences
- Baylor Miraca Genetics Laboratories
- Beckman Coulter, Inc.
- Becton, Dickinson and Company
- BGI Genomics Co. Ltd
- Bio-Rad Laboratories, Inc
- Bio-Reference Laboratories
- Bio-Techne
- Bioarray Genetics
- Biocartis
- Biocept, Inc
- Biodesix Inc
- BioFluidica
- BioIVT
- Biolidics Ltd
- bioMerieux Diagnostics
- Bioneer Corporation
- Bioview
- Bolidics
- Boreal Genomics
- Bristol-Myers Squibb
- Cancer Genetics
- Caris Molecular Diagnostics
- Castle Biosciences, Inc.
- CellMax Life
- Cepheid (now Danaher)
- Charles River Laboratories
- Chronix Biomedical
- Circulogene
- Clinical Genomics
- And Many More Companies!
Key Topics Covered:
1. Introduction and Market Definition
2. Market Overview
2.1 Players in a Dynamic Market
2.2 Personalized Medicine and Companion Diagnostics
2.3 Chromosomes, Genes and Epigenetics
2.4 Cancer Genes
2.5 Structure of Industry Plays a Part
3. Market Trends
3.1 Factors Driving Growth
3.1.1 Level of Care
3.1.2 Immuno-oncology
3.1.3 Liability
3.1.4 Aging Population
3.2 Factors Limiting Growth
3.2.1 State of knowledge
3.2.2 Genetic Blizzard.
3.2.3 Protocol Resistance
3.2.4 Regulation and coverage
3.3 Instrumentation and Automation
3.3.1 Instruments Key to Market Share
3.3.2 Bioinformatics Plays a Role
3.4 Diagnostic Technology Development
4. Companion Diagnostics Recent Developments
4.1 Recent Developments - Importance and How to Use This Section
4.1.1 Importance of These Developments
4.1.2 How to Use This Section
- Biocartis Collaborating with Endpoint Health on CDx Tests for Idylla Platform
- FDA Approves Foundation Medicine Liquid Biopsy Test as CDx for Three Targeted Therapies
- Promega to Develop MSI Assay as CDx
- HTG Molecular Q2 Revenues Drop 66 Percent
- Guardant Health to Develop CDx for Janssen
- Burning Rock Bio, CStone Pharmaceuticals to Codevelop CDx
- FDA Approval for FoundationOneCDx
- FDA finalizes CDx Guidance
- QIAGEN Launches CDx Therascreen BRAF Test
- Myriad Genetics Seeks Approval for Companion Diagnostic
- ARUP Labs Seek PMA for Hemophilia Gene Therapy CDx
- QIAGEN Builds on Global Collaboration with Amgen
- Foundation Medicine nabs 19th companion Dx
- Maze Therapeutics Uses CRISPR for Precision Medicine Companion Diagnostics
- Myriad Wins Japanese Approval for BRACAnalysis
- Fujitsu Improves Efficiency in Cancer Genomic Medicine
- Thermo Fisher's automated sequencer to offer same-day, pan-cancer test results
- Takeda, Prometheus Enter IBD Drug-Companion Diagnostic Partnership
- Thermo Fisher, Eli Lilly Ink CDx Collaboration in NSCLC, Thyroid Cancer
- Roche VENTANA PD-L1 (SP142) Assay approved as companion diagnostic
- Universal Genetic Testing for All Breast Cancer Patients
- Exact Sciences buys Genomic Health
- Biodesix Highlights Pipeline and Companion Diagnostic Development
- Multi-Gene Liquid Biopsy Breast Cancer Panel
- New Gene Panel Identifies High Risk Prostate Cancer
- Guardant Health Liquid Biopsy Test to be Covered by EviCore
- Inivata Completes 39.8M Series B Funding Round
- Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance
- CellMax, Medigen Biotech Partner in Colorectal Cancer Clinical Trials
5. Profiles of Key Players
6. The Global Market for Companion Diagnostics
6.1 Global Market Overview by Country
6.2 Global Market by Application - Overview
6.3 Global Market Funding Source - Overview
7. Global Companion Diagnostic Markets - By Application
7.1 Oncology
7.2 Neurology
7.3 Cardiology
7.4 Other Application
8. Global Companion Diagnostic Markets - Funding Source
8.1 Global Market Pharmaceutical
8.2 Global Market Venture
8.3 Global Market Clinical
8.4 Global Market Other Funding
For more information about this report visit https://www.researchandmarkets.com/r/ur5vbq
